Overview

The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

Status:
Enrolling by invitation
Trial end date:
2025-05-15
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Carboplatin
Etoposide
Etoposide phosphate